{ "Phase 3 Study of Ivonescimab or Bevacizumab for Metastatic Colorectal Cancer", "This study is testing two different drug combinations for people with metastatic colorectal cancer (cancer that has spread to other parts of the body) who have not yet received treatment for their metastatic disease. You would receive either Ivonescimab plus FOLFOX chemotherapy, or Bevacizumab plus FOLFOX chemotherapy. Both Ivonescimab and Bevacizumab are given through an IV. Researchers want to see if one combination is better at slowing down the cancer's growth or spread. You would need to have a good performance status (meaning you are able to do most daily activities) and at least one measurable tumor outside of your brain. People with certain genetic markers (MSI-H or dMMR) are not eligible for this study. The study aims to enroll about 600 participants.", "design": "This is a Phase 3, randomized, active-controlled, and double-blind study. About 600 participants will be randomly assigned to one of two treatment groups.", "commitments": "You would receive IV infusions every two weeks for up to 8 cycles, followed by maintenance treatment every two weeks for up to two years.", "compensation": "Not stated in the trial record.", "follow_up": "Your progress will be monitored for up to approximately 2.5 years to see how long the treatment keeps the cancer from growing or spreading.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.